HOME DCVAX ® TECHNOLOGY PRODUCT CANDIDATES CLINICAL TRIALS INVESTORS & MEDIA ABOUT US DCVax® – Prostate DCVax®-Prostate is designed specifically for late stage, hormone independent prostate cancer. Such cancer involves the spread of micro-metastases beyond the prostate tissue. In most patients, there is no focal tumor which can be surgically removed and used to make lysate, or into which dendritic cells can be directly injected. Instead, the cancer cells are diffuse. We have developed a DCVax product line using a particular proprietary antigen — PSMA (Prostate Specific Membrane Antigen) — which is found on essentially all late stage (hormone independent) prostate cancer. The PSMA is produced through recombinant manufacturing methods, and is then combined with the fresh, personalized dendritic cells to make DCVax-Prostate. Follow us On: DCVAX® TECHNOLOGY About DCVax® Dendritic Cell Immunotherapy Patient Stories & Physician Comments PRODUCT CANDIDATES DCVax® – L DCVax® – Direct DCVax® – Prostate CLINICAL TRIALS Pipeline DCVax® – L Phase III DCVax® – Direct Phase I/II INVESTORS & MEDIA Contacts SEC Filings Stock Information Press Releases Webcasts ABOUT US Overview Company Management Publications Related Links Contact Us © 2017 Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 Phone: 240-497-9024 Forward-looking Statement Legal Disclaimer Privacy Policy

HOME DCVAX ® TECHNOLOGY PRODUCT CANDIDATES CLINICAL TRIALS INVESTORS & MEDIA ABOUT US Patient Stories & Physician Comments Patient Story Brad Silver “DC-Vax saved my life, gave me the ability to continue to be a husband, father, coach and a friend. Eight years ago I never thought that was possible, but here I am.” Physician Comments Dr.John Trusheim Dr. John Trusheim, Director of Neuro-Oncology at the Virginia Piper Cancer Institute, explains the importance of immunotherapies and the apparent effectiveness of DC-Vax. Follow us On: DCVAX® TECHNOLOGY About DCVax® Dendritic Cell Immunotherapy Patient Stories & Physician Comments PRODUCT CANDIDATES DCVax® – L DCVax® – Direct DCVax® – Prostate CLINICAL TRIALS Pipeline DCVax® – L Phase III DCVax® – Direct Phase I/II INVESTORS & MEDIA Contacts SEC Filings Stock Information Press Releases Webcasts ABOUT US Overview Company Management Publications Related Links Contact Us © 2017 Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 Phone: 240-497-9024 Forward-looking Statement Legal Disclaimer Privacy Policy